Biotechnology Innovation Organization

May marks both #LupusAwarenessMonth and Women’s Health Month. In the latest Bio.News story, @LupusOrg discusses the ongoing challenges facing lupus patients, the latest advances in research and treatment, and why greater awareness remains critical - particularly as lupus disproportionately affects women, especially women from historically underserved communities. Read the full story on Bio.News: bio.news/latest-news/lu…

#MustRead -> Ahead of #BIO2026, INDY NXT driver and patient advocate @JamesRoe_IE spoke with Bio.News about managing severe asthma while competing at one of the highest levels of racing - and how his experience as a patient continues to shape his advocacy. In the conversation, Roe reflects on the role innovation and modern biotech breakthroughs have played in his own journey, why patient voices matter in driving progress, and what it means to be truly “Driven by Purpose.” Read the full conversation on Bio.News: bio.news/latest-news/pa…

#MustRead in Bio.News: "What is PDUFA - and why does it matter for biotech innovators, FDA & patients?" Featuring BIO's Annetta Beauregard, the feature examines just how important the Prescription Drug User Fee Act (PDUFA) is to patients and the biotech ecosystem. Read the full piece: bio.news/latest-news/wh… #PDUFA #biotech

#MustRead: Kicking off National Women’s Health Month, Bio.News highlighted BIO’s panel, Capital to Commercial: The Women’s Health BIOtech Ecosystem, at the inaugural Health Executive and Research Summit in San Diego: bio.news/latest-news/bi…

The future of biotechnology will be defined by the choices we make today – on policy, investment, and the ecosystem needed for innovation to thrive. #FightofOurLives brings forward the voices and stories that demonstrate why continued leadership in #biotech matters. Hear the stories, see the impact, understand the promise: fightofourlives.com

#BIO2026 will kick off on June 22 with an AI Summit, bringing together leaders across biotechnology, manufacturing, policy, and patient advocacy to explore how AI and emerging technologies are transforming the full innovation ecosystem - from discovery and clinical development to manufacturing scale-up and global competitiveness. Learn more and register: convention.bio.org/registration Sessions will examine: - How AI, automation, and advanced analytics are accelerating cell and gene therapy manufacturing - The policy and regulatory frameworks needed to support breakthrough platform technologies - The future of U.S. biomanufacturing, supply chain resilience, and global competitiveness - How patient experience is shaping the next generation of rare disease drug development and regulatory engagement

Upcoming webinar: Ahead of #BIO2026, join biotech leaders for a practical conversation on how to approach BIO Partnering™ with purpose. This is a fantastic opportunity to gain actionable insights that you can apply on the ground in San Diego: bio-org.zoom.us/webinar/regist… This webinar will cover how to: -Prepare for BIO 2026 with a clear partnering strategy -Understand what biopharma teams look for in licensing opportunities -Position your science and data effectively -Make the most of BIO Partnering™

As Dr. Rodino-Klapac noted, “The Ohio biotech ecosystem is what I dreamt of when I came here 26 years ago…It’s a great community and there’s no limit to what we can do in Ohio.”

The final stop in Columbus brought the BIO team to @Sarepta for a fireside chat between BIO President & CEO John F. Crowley and Dr. Louise Rodino-Klapac, Ph.D, president & head of R&D and technical operations for Sarepta. Moderated by President & CEO of @OhioLifeScience Eddie Pauline, the discussion focused on the “man-made” barriers that can slow innovation reaching patients - and the shared responsibility to address them. The two also underscored why Ohio is uniquely positioned to lead in gene therapy and precision medicine, reflecting the strength of its research institutions and collaborative ecosystem. #BIOontheAmericanRoad

Sarepta’s 140,000 sq ft Genetics Therapies Center of Excellence in Columbus - its primary R&D hub - anchors this work, advancing discovery, clinical development, and the transition to commercial-scale manufacturing, and reinforcing the critical role the Midwest - and Ohio - play in advancing U.S. biotechnology leadership.

Ohio's life sciences industry by the numbers: • 63,800+ workers strong • 12.8% growth since 2019 • $105K average wages • 7,600+ patent awards (2019–2023) Learn more: ohiolifesciences.org/about/

Up next -> the BIO team arrived at @OhioLifeScience for a roundtable discussion with more than 30 biotech entrepreneurs and leaders committed to advancing Ohio’s life sciences, biomanufacturing, and innovation economy. The conversation highlighted the strength of Ohio’s ecosystem - driven by collaboration across research institutions, industry, and economic development partners - with a deeper dive alongside @OhioState on investments in research and efforts to accelerate clinical trials. #BIOontheAmericanRoad

A strong start to the day in Columbus. The BIO team began at the Jerry Mendell Center for Gene Therapy at Nationwide Children's Hospital (@nationwidekids), where leadership highlighted how Central Ohio has emerged as a national hub for cell and gene therapy innovation. From pioneering three of the first approved CGTs in the U.S. to building a model that integrates early-stage research with clinical care, the Center has helped generate nearly 30 startup spinouts and significantly expanded research investment over the past decade. #BIOontheAmericanRoad

BIO on the American Road has arrived in Columbus, Ohio - bringing together leaders from across the Buckeye State’s rapidly growing life sciences ecosystem. Stay tuned for more updates as the team, led by BIO President & CEO John F. Crowley, engages with local innovators and leaders to discuss the advancement of shared priorities - and highlights Ohio’s talent pipeline and commercialization strength. #BIOontheAmericanRoad

Congratulations to @Merck on the FDA approval of IDVYNSO - the first and only non-INSTI once-daily, complete two-drug regimen for adults living with HIV. #BioInnovation

.@IAmBiotech CEO John Crowley discusses the latest innovations in biotech & therapies for rare diseases: cnb.cx/3OscuCV

As part of its #FightOfOurLives campaign, @IAmBiotech shares the story of Katy Grainger’s life-threatening antibiotic-resistant infection. Policy can help U.S. biotech drive solutions to the most urgent health threats, including the growing crisis of AMR. fightofourlives.com/stories/katy/

50 years ago, biotech began with a bold idea. At #BIO2026, we look ahead to what comes next. Join CEO of @genentech Ashley Magargee and Vice President, Healthcare at @NVIDIA Kimberly Powell for a forward-looking conversation on how AI and cross-sector collaboration are reshaping drug discovery - and accelerating impact for patients. Moderated by @katiecouric, award-winning journalist and co-founder of Katie Couric Media, this Main Stage discussion, sponsored by Genentech, will explore the partnerships and breakthroughs defining biotech’s next chapter. Because when you’re Driven by Purpose, the next 50 years start now. Learn more: convention.bio.org/program/2026-p…

At #BIO2026, 50 years of biotech innovation meets the next era of discovery - Driven by Purpose. With 135 sessions across 18 focus areas, this year's program allows Premier and General Access pass holders to experience discussions and activations featuring leaders from biotech companies, investment firms, service providers, government, regulatory agencies, and the patient community to address the issues shaping what comes next. Learn more and register today: convention.bio.org